deltatrials
Recruiting PHASE2 INTERVENTIONAL 1-arm NCT05257590

CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma

A Phase 2, Open-Label Study of CVM-1118 in Combination With Nivolumab in Subjects With Unresectable Advanced Hepatocellular Carcinoma

Sponsor: TaiRx, Inc.

Conditions Advanced Cancer Hepatocellular Carcinoma
Interventions CVM-1118 Nivolumab Injection [Opdivo]
Updated 10 times since 2022 Last updated: Dec 15, 2025 Started: May 23, 2022 Primary completion: Mar 31, 2026 Completion: Mar 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Advanced Cancer and Hepatocellular Carcinoma and is currently actively recruiting participants. TaiRx, Inc. leads this study, which shows 10 recorded versions since 2022 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Mar 2022 – ~May 2022 · 2 months · monthly snapshotNot Yet Recruiting~May 2022 – ~Aug 2023 · 15 months · monthly snapshotRecruiting~Aug 2023 – ~Jan 2024 · 5 months · monthly snapshotRecruiting~Jan 2024 – ~Jul 2024 · 6 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotRecruiting~Sep 2024 – ~May 2025 · 8 months · monthly snapshotRecruiting~May 2025 – ~Sep 2025 · 4 months · monthly snapshotRecruiting~Sep 2025 – ~Dec 2025 · 3 months · monthly snapshotRecruiting~Dec 2025 – ~Jan 2026 · 31 days · monthly snapshotRecruiting~Jan 2026 – present · 6 months · monthly snapshotRecruiting

Change History

10 versions recorded

  1. Jan 2026 — Present [monthly]

    Recruiting PHASE2

  2. Dec 2025 — Jan 2026 [monthly]

    Recruiting PHASE2

  3. Sep 2025 — Dec 2025 [monthly]

    Recruiting PHASE2

  4. May 2025 — Sep 2025 [monthly]

    Recruiting PHASE2

  5. Sep 2024 — May 2025 [monthly]

    Recruiting PHASE2

▶ Show 5 earlier versions

  1. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  2. Jan 2024 — Jul 2024 [monthly]

    Recruiting PHASE2

  3. Aug 2023 — Jan 2024 [monthly]

    Recruiting PHASE2

  4. May 2022 — Aug 2023 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  5. Mar 2022 — May 2022 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • TaiRx, Inc.
Data source: TaiRx, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations